Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

September 29, 2022

WuXi quintuples Worcester investment to $300M, set to open facility in 2024

Photo | Courtesy of WuXi Biologics Jie Chen, senior vice president and head of MFG11 and MFG18 sites for WuXi Biologics.

Chinese life sciences firm WuXi Biologics has increased the value of its investment in its Worcester facility from the original $60 million to now $300 million.

WuXi held a topping off ceremony for the new facility on Tuesday, as it reached the completion of the steel erection of its new commercial biomanufacturing facility, which is scheduled to open in 2024. 

With the increased investment, the originally planned 107,000-square-foot clinical biomanufacturing suite announced in 2019 will now be a 189,500-square-foot facility.

The WuXi Worcester facility inside The Reactory biomanufacturing campus will employ 250 workers when it's up at full operation.

WuXi is a global contract research, development and manufacturing organization that partners with other companies to help them produce and manufacture products. Plans for what kinds of products will be made at the new facility have not been announced yet.

Sign up for Enews

WBJ Web Partners

Related Content


Order a PDF